Brokerages forecast that Crispr Therapeutics AG (NASDAQ:CRSP) will post earnings of ($0.85) per share for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Crispr Therapeutics’ earnings, with estimates ranging from ($1.01) to ($0.52). Crispr Therapeutics reported earnings of ($0.82) per share during the same quarter last year, which suggests a negative year over year growth rate of 3.7%. The business is expected to report its next quarterly earnings report on Tuesday, August 6th.

According to Zacks, analysts expect that Crispr Therapeutics will report full year earnings of ($3.82) per share for the current fiscal year, with EPS estimates ranging from ($4.18) to ($3.17). For the next fiscal year, analysts forecast that the firm will post earnings of ($3.91) per share, with EPS estimates ranging from ($5.04) to ($2.16). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Crispr Therapeutics.

Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Monday, April 29th. The company reported ($0.93) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.90) by ($0.03). Crispr Therapeutics had a negative return on equity of 50.90% and a negative net margin of 8,839.02%. The firm had revenue of $0.30 million during the quarter, compared to analysts’ expectations of $1.50 million. During the same period last year, the company earned ($0.62) earnings per share. The business’s revenue for the quarter was down 78.6% compared to the same quarter last year.

CRSP has been the topic of a number of research reports. BidaskClub lowered shares of YRC Worldwide from a “buy” rating to a “hold” rating in a research report on Tuesday, April 30th. Needham & Company LLC reiterated a “buy” rating and set a $10.00 price objective (down from $15.00) on shares of Nabriva Therapeutics in a research note on Wednesday, May 1st. Roth Capital started coverage on shares of Crispr Therapeutics in a research note on Monday, June 10th. They set a “buy” rating and a $50.00 price objective on the stock. Evercore ISI started coverage on shares of Homology Medicines in a research note on Thursday, April 11th. They set an “outperform” rating and a $29.00 price objective on the stock. Finally, BTIG Research increased their price objective on shares of Crispr Therapeutics from $30.00 to $33.00 and gave the company a “buy” rating in a research note on Monday, April 22nd. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Crispr Therapeutics currently has an average rating of “Hold” and an average price target of $49.88.

In other news, President Rodger Novak sold 50,000 shares of Crispr Therapeutics stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $50.00, for a total transaction of $2,500,000.00. Following the completion of the sale, the president now directly owns 848,007 shares in the company, valued at $42,400,350. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Samarth Kulkarni sold 20,000 shares of Crispr Therapeutics stock in a transaction on Monday, April 29th. The stock was sold at an average price of $42.03, for a total transaction of $840,600.00. Following the sale, the chief executive officer now owns 186,542 shares of the company’s stock, valued at $7,840,360.26. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 160,000 shares of company stock valued at $7,511,000. 21.40% of the stock is owned by insiders.

Large investors have recently bought and sold shares of the company. Valeo Financial Advisors LLC lifted its stake in shares of Crispr Therapeutics by 71.4% during the first quarter. Valeo Financial Advisors LLC now owns 725 shares of the company’s stock worth $26,000 after buying an additional 302 shares during the period. Lenox Wealth Management Inc. raised its holdings in shares of Crispr Therapeutics by 1,731.7% during the first quarter. Lenox Wealth Management Inc. now owns 2,198 shares of the company’s stock worth $79,000 after purchasing an additional 2,078 shares during the last quarter. Dubuque Bank & Trust Co. raised its holdings in shares of Crispr Therapeutics by 101.6% during the first quarter. Dubuque Bank & Trust Co. now owns 2,873 shares of the company’s stock worth $103,000 after purchasing an additional 1,448 shares during the last quarter. Flagship Harbor Advisors LLC raised its holdings in shares of Crispr Therapeutics by 22.1% during the first quarter. Flagship Harbor Advisors LLC now owns 3,309 shares of the company’s stock worth $118,000 after purchasing an additional 600 shares during the last quarter. Finally, Amundi Pioneer Asset Management Inc. raised its holdings in shares of Crispr Therapeutics by 37.5% during the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 4,400 shares of the company’s stock worth $126,000 after purchasing an additional 1,200 shares during the last quarter. Institutional investors and hedge funds own 48.96% of the company’s stock.

Crispr Therapeutics stock traded down $0.26 during midday trading on Thursday, reaching $49.13. The stock had a trading volume of 28,845 shares, compared to its average volume of 445,793. The company has a market capitalization of $2.59 billion, a price-to-earnings ratio of -14.47 and a beta of 3.11. The stock has a fifty day simple moving average of $45.76. Crispr Therapeutics has a 52-week low of $22.22 and a 52-week high of $59.00. The company has a debt-to-equity ratio of 0.08, a quick ratio of 15.84 and a current ratio of 15.84.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Further Reading: Stock Selection – What is cash flow?

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.